Type 1 diabetes destroys the body’s insulin-producing cells, forcing patients to rely on injections for life. Pancreatic islet transplantation can help, but donor organs are rare and require chronic immunosuppression. As part of the European Vanguard project, led by the University of Geneva (UNIGE), scientists have developed an artificial pancreas capable, in experimental settings, of restoring glucose levels. Recognised by the European Commission’s Innovation Radar, this work represents a major step forward in the fight against this disease, which affects more than 9 million people worldwide and could double by 2040.

Artificial turf football pitches are better than natural turf from a sustainability perspective – at least as long as the artificial turf material is recycled and the natural turf is cut using fossil fuel-powered lawn mowers. This is demonstrated by researchers at Linköping University, Sweden, in a new study comparing the environmental impact of the different pitches with the help of life cycle analyses.

A research team from the Songshan Lake Materials Laboratory has developed an AI-guided "Recommendation System" to discover new metallic glasses (MG). By combining element embeddings learned from Wikipedia by a language model with graph neural networks analyzing hidden material relationships. This approach addresses longstanding challenges related to the vast chemical space and limited experimental datasets, opening new horizons for materials design and accelerating the development of next-generation MGs.

The topics of human-level artificial general intelligence (AGI) and artificial superintelligence (ASI) have captivated researchers for decades. Interest has surged with the rapid progress and deployment of large language models (LLMs), which now handle tasks such as coding, scientific explanation, creative writing, and multimodal reasoning. “Solve AI and it will solve everything” remains a popular, if contested, credo—driving large-scale investment, shaping public narratives, and motivating optimism about transformative advances.

Applying this vision to the healthcare and pharmaceutical industries, Insilico Medicine—a leading generative AI-driven drug discovery company — defines the pharmaceutical superintelligence (PSI) as the next step of AI-driven drug discovery, it showcases a fully-autonomous platform capable of discovering and designing a perfect small molecule or a biologic drug, together with the biomarker for patient selection, producing a significant disease-modifying or curative response for any disease without failure and without the need for further human experimentation.

Working toward this ultimate goal, Insilico continuously upgrades its Pharma.AI platform by integrating state-of-the-art algorithms, expanding and refining its data sources, and validating its models in real-world case studies. Recently, Insilico announced the final 2025 edition of its Pharma.AI Updates, scheduled for December 10, 2025, from 10:00 to 11:00 a.m. ET. This webinar will provide an in-depth look at major updates across key applications, including PandaOmics, Generative Biologics, Chemistry42, and Science42: DORA, through interactive demos and real-world case studies.